LONDON and NEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and for neuropathic corneal pain, a severe ocular condition without an FDA approved therapy, is pleased to announce that it will be presenting at Biotech Showcase in San Francisco, January 8-10 2024. The OKYO management team will also be participating in one-on-one partnering meetings throughout the conference.
Presentation Information
Presenter: Gary S. Jacob Ph.D., CEO of OKYO Pharma
Title: Clinical Development Status of OK-101 to Treat Dry Eye Disease
Day: Tuesday, January 9th
Time: 9:30am PST
Location: Room Yosemite-A
OKYO Pharma has just completed a phase 2, multi-center, double-masked, placebo-controlled trial of topical ocular OK-101 to treat 240 patients with dry eye disease (DED).
Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference takes place each year in San Francisco during the course of one of the industry's largest gatherings and busiest weeks.
"We are delighted that OKYO Pharma will be joining us in San Francisco and presenting at Biotech Showcase this ...
